Evaluation of gene delivery strategies to efficiently overexpress functional HLA-G on human bone marrow stromal cells

Joana S Boura1,2, Melisa Vance1, Weihong Yin1, Catarina Madeira2, Cláudia Lobato da Silva2, Christopher D Porada1 and Graça Almeida-Porada1

Mesenchymal stromal cells (MSC) constitutively express low levels of human leukocyte antigen-G (HLA-G), which has been shown to contribute to their immunomodulatory and anti-inflammatory properties. Here, we hypothesized that overexpression of HLA-G on bone marrow-derived MSC would improve their immunomodulatory function, thus increasing their therapeutic potential. Therefore, we investigated which gene transfer system is best suited for delivering this molecule while maintaining its immunomodulatory effects. We performed a side-by-side comparison between three nonviral plasmid-based platforms (pmax-HLA-G1; MC-HLA-G1; pEP-HLA-G1) and a viral system (Lv-HLA-G1) using gene transfer parameters that yielded similar levels of HLA-G1-expressing MSC. Natural killer (NK) cell–mediated lysis assays and T cell proliferation assays showed that MSC modified with the HLA-G1 expressing viral vector had significantly lower susceptibility to NK-lysis and significantly reduced T cell proliferation when compared to nonmodified cells or MSC modified with plasmid. We also show that, in plasmid-modified MSC, an increase in Toll-like receptor (TLR)9 expression is the mechanism responsible for the abrogation of HLA-G1’s immunomodulatory effect. Although MSC can be efficiently modified to overexpress HLA-G1 using viral and nonviral strategies, only viral-based delivery of HLA-G1 is suitable for improvement of MSC’s immunomodulatory properties.

Molecular Therapy — Methods & Clinical Development (2014) 1, 14041; doi:10.1038/mtm.2014.41; published online 3 September 2014

INTRODUCTION

Human mesenchymal stromal cells (MSC) have been recognized for their trophic, anti-inflammatory, and immunomodulatory properties, and have been used in the treatment of a wide range of diseases, including those that involve degenerative or aberrant immune/inflammatory responses.1 MSC preferentially home to sites of injury and/or inflammation, whereupon they promote tissue repair through mechanisms that involve both secretion of bioactive molecules and cell-to-cell interactions, which regulate and/or modulate local innate and adaptive immune responses, and promote tissue-specific cell proliferation and repair.2,3 Although MSC’s therapeutic benefit has been reported in numerous studies,4,5 some of the larger-scale clinical trials to-date either produced conflicting results or shown only modest benefits.6 Failure to achieve a therapeutic effect is likely due in large part to inadequate engraftment, poor tissue survival, or insufficient trophic and/or immunomodulatory effects of the transplanted MSC. Therefore, strategies that will enable MSC therapies to consistently achieve robust and reliable efficacy are urgently needed.

Human leukocyte antigen-G (HLA-G, a nonclassical HLA class I molecule (HLA-1b), known for its tolerogenic and powerful immune inhibitory function, exists in seven different isoforms, of which the full-length transmembrane HLA-G1, and its soluble counterpart HLA-G5, are the most extensively studied.7,8 Both HLA-G1 and HLA-G5 are potent suppressors of allogeneic T-cell response through induction of CD8+ T-cell apoptosis and arrest of T- and B-cell proliferation, inhibitors of natural killer (NK) cell cytotoxicity, inducers of regulatory T cells, and are known to modify maturation of antigen-presenting cells.9–11 In addition, it has also been reported that higher levels of HLA-G expression are associated with a reduction of acute and chronic transplant rejection, while low levels of this molecule can be efficiently modified to overexpress HLA-G1 using viral and nonviral strategies, only viral-based delivery of HLA-G1 is suitable for improvement of MSC’s immunomodulatory properties.

Since MSC have been shown to constitutively express HLA-G at low levels;12,13 and this molecule is known to be involved in MSC-mediated immunomodulatory function, we hypothesized that
genetically engineering MSC to overexpress HLA-G1 (MSC-HLA-G1) could be used as an approach to improve upon MSC’s immunomodulatory properties and thereby enhance the efficacy of existing MSC-based therapies. In addition, since MSC, despite their immunomodulatory properties, can still be a target of activated NK and cytotoxic T cells, it is possible that overexpression of HLA-G1 could lead to increased survival of MSC after infusion. Therefore, here we investigated which gene transfer system is best suited for delivering this molecule while maintaining its immunomodulatory effect by performing a side-by-side comparison between a lentiviral vector (Lv-HLA-G1), a murine retroviral vector (Rv-HLA-G1), and three nonviral plasmid constructs including a conventional plasmid

Figure 1  Schematic representation of minicircle (MC) production and map of pDNA constructs used for nonviral gene delivery. The MC-PP-HLA-G1 contains the ColE1 and EcoE1 origin of replication sequences required for bacterial propagation, the kanamycin-resistance gene, the φC31 integrase recognition sites attB and attP, and a block of 32 tandem repeats of the recognition sequence for the I-SceI homing endonuclease. Following MC-PP-HLA-G1 propagation, arabinose-mediated induction of φC31 integrase activity generates a minicircle containing the HLA-G1 expression cassette (MC-HLA-G1) and a circular plasmid backbone (BB); the latter is subsequently degraded by host exonucleases (also induced by arabinose) (a). Agarose gel electrophoresis analysis of linearized MC-HLA-G1 and MC-Empty with no visible PP contaminants (b). pmax-HLA-G1 is a conventional plasmid that harbors the pUC origin of replication, a kanamycin-resistance gene, a hCMV promoter driving the HLA-G1 gene, and an SV40 poly-adenylation sequence (c). The episomal plasmid pEP-HLA-G1 includes the R6K origin of replication, an ampicillin-resistance gene, a S/MAR sequence, a hCMV enhancer, an EF1 promoter driving the HLA-G1 gene, and an IRES module (d).
upregulation was found in MSC nucleofected with the empty MC construct provided the best overall rate of transfection, MSC were significantly higher than that attained with pmax-HLA-G1 (37 ± 2.7% and 33 ± 2.9% of the transfected cells, respectively, to express HLA-G1, by contrast, only 13 ± 0.9% of the cells transfected with pEP-HLA-G1 overexpressed HLA-G1 (Figure 2). Duration and level of transgene expression profile was also determined 12 days post-nucleofection, at which time HLA-G1 expression mediated by pEP-HLA-G1 was lost, while MC-HLA-G1 and pmax, still drove levels of HLA-G1 expression of 31 ± 4.6% and 31 ± 5.5%, respectively (n = 4). Importantly, for all DNA constructs, cell viability was always found to be greater than 85%.

To further evaluate gene modification efficacy, both transfected cell recovery and yield of transfection were also calculated at 48 hours post-nucleofection (Figure 3). Transfected cell recovery corresponds to the ratio of the number of live nucleofection-modified cells to the number of cells before transfection, while the yield of transfection is given by the percentage of viable HLA-G1-positive cells relative to nontransfected cells. Together, these two parameters evaluate the number of MSC that maintained viability and successfully overexpressed the transgene, and therefore provide a more accurate assessment of the transfection performance. MSC modified with MC-HLA-G1 displayed values of cell recovery (53 ± 4.3%) that were significantly higher than MSC transfected with pEP-HLA-G1 (31 ± 2.9%; P < 0.05) (n = 4). Additionally, no significant differences in cell recovery were seen between MC-HLA-G1-modified cells (53 ± 4.3%) and control cells that were nucleofected without DNA (58 ± 5.2%) (Figure 3a). However, we found that the transfection rate (Figure 3b) obtained for MC-HLA-G1 (46 ± 3.6%) was significantly higher than that attained with pmax-HLA-G1 (37 ± 1.8%; P < 0.05) or pEP-HLA-G1 (63 ± 0.8%; P < 0.05). Since the MC-HLA-G1 construct provided the best overall rate of transfection, MSC were nucleofected with an MC-empty vector (no HLA-G1) to exclude any possible effect of the MC backbone on endogenous HLA-G1 expression. Importantly, while the percentages of cell viability and cell recovery were similar to that observed for MC-HLA-G1, no HLA-G1 upregulation was found in MSC nucleofected with the empty MC vector (data not shown).

Among viral vectors, retroviruses and lentiviruses (a subfamily of retrovirus) are the most commonly used for long-term transgene expression, as they are able to efficiently and stably integrate into the host genome. However, while murine-retroviruses were the first class of viral vectors to be developed, and one of the most widely applied gene transfer carriers in the clinic, lentiviruses have the important advantage of modifying both nondividing and dividing cells. Therefore, stably transfected MSC expressing HLA-G1 were generated using lentivirus (Lv-HLA-G1). In order to perform a side-by-side comparison between nonviral and viral systems, MSC were transfected at a multiplicity of infection (MOI) known to modify ~50–60% of MSC, and thus generate MSC with HLA-G expression levels similar to day 2 nonvirally transfected cells (Figure 4).

MSC modified with a lentiviral vector expressing HLA-G, but not with the nonviral plasmids, have significantly lower susceptibility to NK-lysis when compared to unmodified cells Since HLA-G has been shown to inhibit NK cytotoxicity, we investigated whether MSC modified to overexpress HLA-G1 (MSC-HLA-G1) would have an increased resistance to NK-mediated lysis in comparison with nonmodified MSC (MSC) (n = 4). MSC nucleofected with MC-HLA-G1, pmax-HLA-G1, or pEP-HLA-G1 were examined at day 2 post-transfection, as were MSC that had been stably transfected with Lv-HLA-G1. A broad range of NK/MSC ratios (effector:target) was tested. Results show that only the viral delivery system render MSC more resistant to activated NK cells, indicating that NK-mediated lysis is differentially affected by the system used to deliver the HLA-G1 gene (Figure 5). This effect is particularly evident at the highest NK/MSC ratio (20:1), where a reduction of ~30% was observed for virally-transduced MSC when compared to nonmodified MSC (P < 0.05). In contrast, when MSC were transfected with MC-HLA-G1 (64 ± 3.3%) and pmax-HLA-G1 (68 ± 5.6%) vectors, NK-mediated lysis was not decreased, compared to nonmodified cells (62 ± 5.5%). Even more remarkably transfection of MSC with pEP-HLA-G1 actually caused a statistically significant increase in their susceptibility to NK lysis (89 ± 6.6%; P < 0.05). Similar results were also obtained for 10:1 ratio. Although at the 5:1; 1:1, 0:2:1, and 0:1:1 NK/MSC ratios, a statistically significant difference between Lv-HLA-G1 engineered MSC and unmodified MSC was no longer present, the cytotoxic
investigated whether MSC's expression repertoire of inhibitory or cell responses, when delivered through nonviral systems, we determined why HLA-G1 was unable to alter T and NK overexpressing HLA-G1. Expression levels of different immunoreceptors on MSC nucleofected without the addition of plasmid DNA. 

Only HLA-G virally-modified MSC are able to significantly reduce T-cell proliferation

In order to determine whether MSC modified to overexpress HLA-G1 (MSC-HLA-G1) would further reduce peripheral blood mononuclear cells (PBMC) proliferation when compared to nonmodified MSC, a one-way (n = 4) or two-way mixed lymphocyte reaction (MLR) was performed (n = 4). The one-way proliferation assay measures the ability of PBMC to respond and proliferate to allogeneic MSC in culture, while the two-way assay determines the ability of MSC to alter the allogeneic immune response (proliferation) when PBMC of two unrelated individuals are cultured together. In similarity to our observations with susceptibility to NK lysis, results with MLR show that PBMC proliferation was also differentially affected by the HLA-G1 gene delivery system used (Figure 6). MLR results shown in Figure 6a (one-way) and Figure 6b (two-way) clearly demonstrate that only HLA-G overexpressed by the lentiviral vector was able to significantly decrease PBMC proliferation when compared with unmodified MSC (P < 0.05). Results from one-way assays show that, when compared to unmodified MSC, cells transfected with MC-HLA-G1 (1.02 ± 0.05) and pmax-HLA-G1 (1.04 ± 0.07) were unable to decrease the levels of PBMC proliferation, while modifying the MSC with pEP-HLA-G1 (1.12 ± 0.05) actually enhanced significantly PBMC proliferation (P < 0.05; Figure 6a). Furthermore, as shown in Figure 6b which depicts representative results obtained by the two-way MLR, HLA-G1 overexpression, via pmax-HLA-G1 (1.23 ± 0.11) and pEP-HLA-G1 (1.29 ± 0.09), significantly decreased the ability of MSC to inhibit allogeneic PBMC proliferation, when compared with unmodified MSC (P < 0.05). Nucleofection of MSC with MC-empty (1.26 ± 0.10) also resulted in an increased PBMC proliferation in two-way assays (P < 0.05), whereas no major differences were observed between cells transfected with MC-HLA-G1, unmodified cells, and MSC nucleofected without the addition of plasmid DNA.

Expression levels of different immunoreceptors on MSC overexpressing HLA-G1

In order to determine why HLA-G1 was unable to alter T and NK cell responses, when delivered through nonviral systems, we investigated whether MSC’s expression repertoire of inhibitory or stimulatory immunoreceptors/ligands had changed as a result of transfection.

NK lytic activity is determined by the balance between activating and inhibitory signals, and the activating NK cell receptors Nkp30, NKG2D, and DNAM-1 are the main receptors responsible for the induction of NK-mediated cytotoxicity against MSC. Therefore, we analyzed the presence/levels of NK cells’ NKG2D activating ligands, including ULBP 1, 2/5/6 and 3, and MICA/B, as well as DNAM-1 activating ligands, CD122 (nectin-2) and CD155 (PVR), on the surface of genetically engineered and unmodified MSC. As shown in Figure 7a, all MSC, independent of the treatment, expressed moderate and low levels of ULBP-2/5/6 and ULBP-3, respectively, and negligible levels of MICA/B and ULBP-1. Furthermore, CD122 was barely detectable regardless of whether MSC were modified to upregulate HLA-G1 or not. CD58, a surface molecule that has been associated with NK-cytotoxic activity, was absent on all MSC populations (Figure 7a), and CD155 was highly expressed in both MSC-HLA-G1 and MSC.

Since the interaction between HLA class I (HLA-I) molecules and specific inhibitory/activating receptors on the NK-cell surface, such as KIRs, CD94, and NKG2A, engages signaling pathways that prevent target cell lysis, the expression of the classical HLA-I molecules HLA-ABC and the nonclassical HLA-Ib molecule HLA-E was also investigated. HLA-ABC was present on more than 80% of all

---

**Figure 3** Cell recovery and transfection yield at day 2 after nucleofection. Comparison of the cell recovery (a) and yields of transfection (b) obtained for all DNA constructs. Each bar represents the mean ± standard error of mean, n = 4; *P < 0.05; ***P < 0.001.

**Figure 4** Stable transduction of MSC overexpressing HLA-G1. MSC were modified using a lentiviral delivery system (Lentiv-HLA-G1). Stable transduction was achieved 3 days after viral infection and transgene expression levels were determined by flow cytometric analysis. Each bar represents the mean ± standard error of mean; n = 4; ***P < 0.001.
modified and unmodified MSC, whereas HLA-E exhibited low levels of expression (Figure 7b). Additionally, the expression of HLA-DR, a class II HLA molecule that plays a pivotal role in eliciting immune responses was negligible (Figure 7b).

Because no significant differences were observed in the expression of any of the molecules described above, the Toll-like receptor (TLR) pathway was investigated (Figure 7c). Importantly, TLR9, a receptor that specifically recognizes nonmethylated CpG dinucleotides present in bacterial sequences, was found to be significantly upregulated in MSC transfected with any of the nonviral delivery systems (P < 0.05). Nevertheless, it is important to note that, among nonviral constructs, MC-HLA-G1 induced the least TLR9 expression (17 ± 3.4%) when compared to MSC modified with MC-empty (25.7 ± 3.4%), pmax-HLA-G (135 ± 11%), or pEP-HLA-G1 (36 ± 11%). By contrast, when a lentiviral vector was used to deliver HLA-G1, the levels of TLR9 expression remained similar to those present in unmodified cells. The levels of TLR4 (a receptor for bacterial lipopolysaccharides) were found to be almost negligible for all conditions, while the percentage of cells expressing TLR3 (a receptor for viral double-stranded RNA (dsRNA), was only increased (P < 0.05) in Lv-HLA-G1 when compared to unmodified cells.

**DISCUSSION**

Given MSC’s intrinsic anti-inflammatory and immunomodulatory properties, these cells have been explored as promising therapeutic tools to treat several immune-based disorders. Therefore, engineering MSC to overexpress proteins that exert strong immune-inhibitory functions, such as HLA-G, could be used to enhance the beneficial effect of MSC and, consequently, improve the clinical outcome of current MSC-based therapies. To achieve this goal, it is thus pivotal to identify the gene delivery strategy that provides the optimal combination of gene transfer performance, safety, and therapeutic efficacy of the transgene. Current options for delivering therapeutic genes include both viral and nonviral approaches, each with advantages and shortcomings.

In the present study, we evaluated the ability of three different nonviral vectors and a lentiviral vector to serve as effective gene delivery platforms to overexpress HLA-G1 in MSC, and used NK lysis, MLR assay, and immunophenotyping to define the effects each of these systems exerts on known MSC immunomodulatory functions.

Although nonviral approaches have been reported to be less efficient at introducing genetic material into cells when compared to viral systems, they could potentially provide superior safety to viral vectors. Therefore, we first focused on establishing transfection conditions that maximized HLA-G1 overexpression. Because, among nonviral gene transfer systems available, nucleofection has emerged as a powerful technique that consistently provides MSC transfection levels of 50–80%, our strategy consisted of combining this technology not only with a standard plasmid DNA molecule (pMax), but also with newer generation DNA constructs, such as minicircles (MC), which have the advantage of a greatly reduced size, and a self-replicating episomal plasmid encoding for scaffold/matrix attachment region (S/MAR; pEP). In addition, both MC and pEP constructs have reduced numbers of unmethylated CpG sequences (169 and 170 respectively), which have been proposed as one of the mediators for triggering the immune response that leads to loss of gene expression following plasmid-mediated delivery.

Here we show that nucleofection using either MC-HLA-G1 or pmax-HLA-G1 plasmid constructs constitutes an effective gene delivery approach to overexpress HLA-G1 on MSC and, although similar levels of HLA-G1-positive cells were obtained with both constructs, MC-HLA-G produced significantly higher cell recovery and yield of transfection. In addition, the percentages of cell recovery and yield of transfection observed for MC-HLA-G were higher than what has previously been reported using the same or alternative electroporation methods such as microinjection. We also showed that although pEP-HLA-G1 induced HLA-G1 overexpression, the overall transfection efficiency was much lower when compared with MC-HLA-G1 or pmax-HLA-G1 constructs. This difference between...
MC-HLA-G1 (2954 bp), pmax-HLA-G1 (3486 bp), and pEP-HLA-G1 (5972 bp) is consistent with the previously described inverse correlation between transfection efficiency and the size of the DNA molecule introduced.31 Surprisingly, transgene expression induced by pEP-HLA-G1 was rapidly lost with time in culture, despite the presence of the S/MAR element.

Since viral systems are still the most routinely used gene transfer platforms and are able to offer robust efficiency and sustained gene expression,19 we performed a side-by-side comparison between nonviral and a lentiviral system in order to investigate which gene transfer system is best suited for delivering HLA-G1, while maintaining its immunomodulatory effects. We found that only virally-transduced MSC were capable of significantly decreasing the susceptibility of MSC to NK-mediated lysis and reducing PBMNC alloproliferation in comparison with unmodified MSC. In addition, preliminary studies using murine retroviral vectors to deliver HLA-G1 resulted in similar levels of immunomodulation to those seen with lentiviral vectors (data not shown). Although the use of nonviral constructs, resulted in a similar percentage of HLA-G1 expressing cells as the viral-based delivery system, NK-mediated lysis and PBMC alloproliferation were both increased following nonviral transfer of HLA-G1. These results led us to investigate the expression of molecules known to have an active role in eliciting immune responses on MSC. Therefore, we evaluated and compared the expression of the NK killing activation ligands ULBP 1, 2, and 3, MICA/B, CD122, and CD155, as well as two of the main NK inhibitory ligands, HLA-ABC and HLA-E, on genetically engineered and unmodified MSC. Since we were unable to detect a correlation between the levels of expression of these molecules and the effects observed in the functional assays, the expression of TLRs were also investigated. TLRs represent the most well studied family of immune sensors of invading pathogens and play an important role in activation of the adaptive immune response.19 These receptors are broadly distributed throughout the cells of the immune system, and their activation is crucial for the engagement of immune response and enhancing adaptive immunity against microbes.23 More recently, it has also been shown that MSC constitutively express TLRs at different levels,35,36 with TLR3 and TLR437 being expressed at higher levels than TLR9.35 Importantly, it has also been shown that TLRs participate in MSC’s immunological function and that although the mechanisms involved are still not completely understood, TLR activation differentially affects MSC immunomodulatory response.37 Some studies indicate that TLR3 and TLR4 activation reduce the inhibitory activity of human BM-MSCs on T-cell proliferation and induce

**Figure 6** PBMNC proliferative response toward MSC-HLA-G1 engineered using different gene delivery systems. Each of the HLA-G1 modified and unmodified MSC (stimulator cells) were cocultured with allogeneic PBMNC (responder cells) in a one-way (n = 8), (a) or two-way (n = 4), (b) assay. After 5 days, the proliferation of alloreactive cells was measured using a colorimetric BrdU cell proliferation ELISA. For all conditions, the arbitrary values of PBMNC proliferation were normalized to unmodified MSC (MSC). Each bar represents the mean ± standard error of mean; *P < 0.05.

|         | OD normalized to MAC |
|---------|----------------------|
| MSC     | 1.0                  |
| MC-HLAG1| 1.2                  |
| MSC MC-Empty | 1.4               |
| MBC pmax-HLAG1 | 1.6             |
| MBC EP-HLAG1 | 1.8               |
| MBC Lv-HLAG1 | 2.0               |
| MBC Nucleofected, no pDNA | 2.2             |
the secretion of proinflammatory molecules capable of promoting the recruitment of inflammatory immune cells,36,38,39 whereas others report that TLR3 and/or TLR4 engagement enhances the immunosuppressive properties of human BM-MSCs.39,40 Waterman et al.41 suggested a model in which TLR ligand concentration, timing, and kinetics of activation are responsible for polarizing MSC toward either proinflammatory (MSC1) or anti-inflammatory (MSC2) phenotypes. More specifically, in TLR4-primed MSC, upregulation of proinflammatory cytokines, such as interleukin (IL)-6 and IL-8, and activation of T-cell proliferation (MSC1 phenotype) are observed, whereas TLR3 engagement results in secretion of anti-inflammatory molecules, such as IL4, IDO, and PGE2, and inhibition of lymphocyte proliferation (MSC2 phenotype).

Here, we did not find changes on TLR3 or TLR4 expression, but rather, a significant increase in TLR9 was found for all nonviral transfected MSC, indicating that TLR9 function in MSCs can be modulated by artificially introducing pDNA into these cells. In fact, despite HLA-G1 overexpression and efforts to minimize CpG content by using newer generation DNA constructs (MC-HLA-G1 and pEP-HLA-G1), it is important to note that the small number of residual CpG sequences may still result in activation of the TLR9 signaling following introduction of these bacterial-based platforms into MSC’s cytoplasm, thereby negating the functional effect of HLA-G1 overexpression. Although TLR9 has thus far only been implicated in MSC mobilization toward inflammation sites,42 we showed a potential correlation between TLR9 activation in transfected MSC, and impaired MSC immunomodulatory potential. This effect was not observed for virally-transduced MSC, most likely due to the fact that viruses have evolutionary characteristics that naturally allow them to bypass recognition by some DNA sensors.18

Figure 7 Characterization of immunoreceptors on MSC-HLA-G1 and unmodified MSC. Cells were analyzed by flow cytometry for expression of NK-activating ligands, including ULPP 1, 2/5/6 and 3 and MICA/B (NKG2D ligands), and CD122 and CD155 (DNAM-1 ligands) (a), for HLA-ABC, HLA-E, and HLA-DR (b), as well as for TLR3, TLR4, and TLR9 (c). Each bar represents the mean ± standard error of mean; n = 4; *P < 0.05.

In conclusion, we demonstrated that HLA-G1 expression on human MSC can be efficiently boosted using both nonviral and viral approaches. Nevertheless, despite the encouraging results obtained with nonviral systems, we show for the first time, to our knowledge, that only viral-based delivery of HLA-G1 improves MSC’s immunomodulatory properties, indicating that the gene transfer approach can influence the immune behavior of MSC. These differences
observed between non-viral and viral systems could be attributed to TLR9 upregulation caused by the CpG sequences present in non-viral plasmids; however, further investigation into the processes involved in DNA sensing in MSC can clarify how signals delivered by TLR can influence genetically-engineered MSC's biological function.

MATERIALS AND METHODS

Human BM-MSC isolation and culture

Bone marrow-derived MSC (BM-MSC) were isolated using anti-Stro-1 antibody (R&D Systems, Minneapolis, MN) and magnetic cell sorting (Miltenyi Biotec, Auburn, CA) as previously described.40 Cell cultures were maintained in gelatin (Sigma-Aldrich, St Louis, MO)-coated flasks and MSCGM (Mesenchymal Stem Cell Growth Medium BulletKit, Lonza, Atlanta, GA) supplemented with penicillin/streptomycin (100 U/ml) (Gibco-Life Technologies, Carlsbad, CA) at 37 °C and 5% CO₂ in a humidified atmosphere. MSC were passaged when they reached 70% confluence by trypsin solution (Lonza) for 7 minutes at 37 °C. Cell number and viability were determined using the Trypan Blue (Gibco-Life Technologies) exclusion method, and cells were replated at 3,000 cells/cm². Phenotypic and differentiative characterization of Strom-1- BM-MSC has been previously reported.40 MSC were found to be positive (>95%) for CD29, CD73, CD90, and CD105; and negative (<0.05%) for CD34, CD45, CD14, CD19, and HLA-DR. Furthermore, upon culture in appropriate medium, these cells differentiated into bone, cartilage, and adipocytes.

All experiments were performed using cells from four different donors (n = 4), at passages 6–9. After genetic modification with HLA-G1, independently of the method used, cells are designated MSC-HLA-G1.

Vector preparation and purification

The coding region of the human HLA-G1 gene (hlag, 1017 bp) was amplified by polymerase chain reaction (PCR) using, as template, a cDNA clone (GenBank NM_002127.3) obtained from OriGene (pCMV6-XL5-HLAG, Rockville, MD). The primers were specifically designed to amplify the full coding region and to introduce restriction sites for further cloning purposes (primer sequences are listed in Table 1). All PCR reactions were performed using High Fidelity Platinum Taq DNA Polymerase (Invitrogen-Life Technologies, Carlsbad, CA) under the following conditions: 94 °C for 2 minutes, followed by 35 cycles of 94 °C for 30 seconds, 57 °C for 30 seconds, and 72 °C for 1 minute; and 72 °C for 10 minutes. Each PCR product was then cloned into the pCR4-TOPO vector (Invitrogen-Life Technologies, Carlsbad, CA) under the following conditions: 94 °C for 2 minutes, followed by 35 cycles of 94 °C for 30 seconds, 57 °C for 30 seconds, and 72 °C for 1 minute; and 72 °C for 10 minutes. Each PCR product was then cloned into the pCR4-TOPO vector (Invitrogen) following manufacturer's instructions. The HLA-G1 sequence was confirmed by DNA sequencing of all five pcR4-TOPO-HLAG1 vectors. Subsequently, the HLA-G1 gene was isolated from the pcR4-TOPO-HLAG1 vectors by restriction digestion and gel purification. Digestion was performed using standard methodology with BamHI/EcoRI, Nhel/BSrGI, Nhel/Xhol, SplI/EcoRI, or EcoRI/Xhol (all from New England Biolabs, Ipswich, MA). Minicircle parental plasmid-HLA-G1 (MC-PP-HLAG1) was amplified using HLA1 using the restriction site of the pMSCV-Neo retroviral vector backbone (Clontech, Mountain View, CA) and pEcoRI restriction sites.

Viral particle production

Lentiviral particles were produced by cotransfecting 293T cells with pSIN-EF2-HLAG1, pMD2.G, and pSAX2 plasmids using FuGENE 6 (Promega, Madison, WI). Vector-containing supernatants were collected 48 hours after transfection. The collected supernatants, for both retrovirus and lentivirus, were filtered with 0.2 μm low protein-binding syringe filters (Pall Corporation, Ann Arbor, MI), concentrated using 100K Amicon Ultra centrifugal filters (Millipore, Billerica, MA), and stored in aliquots at −80 °C until further use.

Nucleofection-mediated transduction

BM-MSC nucleofection was performed according to Human MSC Nucleofector Kit (Lonza) protocol. Briefly, 4 × 10⁵ MSC were resuspended in 100 μl of nucleofection buffer with 2 μg pDNA (MC-HLA-G1, pmax-HLA-G1, or pEP-HLA-G1) and pulsed with the U-23 program of the Amaxa Nucleofection device (Lonza). After nucleofection, cells were carefully transferred to MSCGM, and the cell number and percent viability estimated using Trypan Blue. Cells were then replated at 3,000 cells/cm² and kept in culture at 37 °C and 5% CO₂ in a humidified atmosphere. HLA-G1 expression levels were measured by flow cytometric analysis 2 and 10 days after nucleofection. Non-nucleofected cells were used as a control, as were MSC only pulsed with U-23 (no pDNA). Cell recovery and rate of nucleofection were determined using equations previously described by Madeira et al.40 MSC nucleofected with plasmids encoding HLA-G1 were designated mVMSC-HLA-G1.

MSC viral transduction

MSC cultures at 60% confluence were incubated overnight with supernatants containing lentiviral particles encoding HLA-G1 diluted in serum-free QBSF-60 medium (Quality Biological, Gaithersburg, MD) and 8 μg/ml protamine sulfate (Calbiochem, San Diego, CA). Transduction was performed at an MOI that yielded similar levels of HLA-G1-expressing MSC for all gene delivery systems. After transduction, cells were washed, and media was changed to MSCGM (Lonza). Stably transduced MSC with HLA-G1 (mVMSC-HLA-G1) were analyzed for transgene expression using flow cytometry.

NK cytotoxicity assay

NK cytotoxicity assays were performed as previously described by Soland et al. Briefly, MSC, mVMSC-HLA-G1 48 hours after transduction, and wMSC-HLA-G1 were plated in a flat-bottomed 96-well microplate (BD Falcon, Franklin Lakes, NJ) (1 × 10⁶ cells/ml; 50 μl/well), and incubated in triplicate

Table 1 List of polymerase chain reaction primers used for plasmid construction

| Primer name | F/R | Sequence (£ to 3') |
|-------------|-----|--------------------|
| HLAG1_F_EcoRI | F   | AAA GAATTC ACCCATGATGGT CATGGGCC |
| HLAG1_F_Nhel | F   | AAA GCTAGC ACCCATGATGGT CATGGGCC |
| HLAG1_F_Spel | F   | AAA ACTAGT ACCCATGATGGT TCATGGCC |
| HLAG1_R_BamHI | R   | AAA GGATCC TCAATCTGAGCTTCTTCCAC |
| HLAG1_R_BsrGI | R   | AAA ACATGT TCAATCTGAGCTTCTTCCAC |
| HLAG1_R_Xhol | R   | AAA GAGCTC TCAATCTGAGCTTCTTCCAC |

The MC-PP-HLAG1 (Figure 1a) was transformed into Escherichia coli ZYCY10P3S2T (System Biosciences), a strain that has been specifically engineered to allow both propagation of the MC-PP and the production of the MC DNA.19 MC-PP-HLAG1 propagation and MC-HLA-G1 production (Figure 1a) was performed according to System Biosciences' instructions.80 After MC-HLA-G1 purification, a restriction digest-mediated linearization step allowed the evaluation of the residual amount of MC-PP in the MC preparations (Figure 1b). MC-empty (no HLAG1) was also produced. The pmax-HLA-G1 plasmid (3486 bp, Figure 1c) was constructed by replacing the GFP from pmaxGFP (3486 bp, Lonza, Amaza GmbH) with HLAG1 using Nehel-Xhol sites. The pEP-HLAG1 plasmid (5972 bp, Figure 1d) was generated by replacing the GFP from pEPito-EGFP-IB (5680 bp, PlasmidFactory, Bielefeld, Germany) with HLAG1 using Nehel and BsrGI restriction sites. pmax-HLAG1 and pEP-HLAG1 were constructed and propagated in E. coli strain DB3.1apor (kindly provided by Dr Michael Kahn, Washington State University) and E. coli strain DH5α (Zymo Research Corporation, Irvine, CA), respectively. The HLAG1 gene was also cloned into the multiple cloning site of the pMSCV-Neo retroviral vector backbone (Clontech, Mountain View, CA) using the restriction sites EcoRI and Xhol. The pSIN-EF2-HLAG1 was obtained by replacing the Nanog gene in pSIN-EF2-Nanog-Put, obtained from Addgene (Addgene, http://www.addgene.org), with HLAG1 using the SplI and EcoRI restriction sites. All cloning products were confirmed by restriction digest-mediated linearization followed by agarose gel electrophoresis and DNA sequencing. All plasmid constructs were purified using an endotoxin-free plasmid purification kit (Macherey-Nagel, Bethlehem, PA). The concentration of purified pDNA solutions was assayed by Nanodrop (Thermo Scientific, Wilmington, DE), and DNA integrity was confirmed using DNA agarose gel stained with ethidium bromide.
with different concentrations of NK-92 MI cells (ATCC, Rockville, MD) (20 x 10^4 cells/ml; 10 x 10^4 cells/ml; 5 x 10^4 cells/ml; 1 x 10^4 cells/ml; 2 x 10^4 cells/ml; 1 x 10^5 cells/ml; 50 x 10^4 cells/ml). 

**REFERENCES**

1. Bianco, P, Cao, X, Fenrette, PS, Mao, JJ, Robey, PG, Simmons, PJ et al. (2013). The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med 19: 35–42.

2. Caplan, AI and Correa, D (2011). The MSC: an injury drugstore. Cell Stem Cell 9: 11–15.

3. Prokop, DJ and OH, JY (2012). Medical therapies with adult stem/progenitor cells (MSCs): a backward journey from dramatic results in vivo to the cellular and molecular explanations. J Cell Biochem 113: 1460–1469.

4. Kramer, J, Dazzi, F, Dominici, M, Schlenke, P and Wagner, W (2012). Clinical perspectives of mesenchymal stem cells. Stem Cells Int 2012: 684827.

5. Le Blanc, K, Frassoni, F, Ball, L, Locatelli, F, Roelofs, H, Lewis, J et al.; Developmental Committee of the European Group for Blood and Marrow Transplantation. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 367: 1579–1586.

6. Allison, M (2009). Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 27: 965–967.

7. Carosella, ED (2011). The tolerogenic molecule HLA-G. Immunol Lett 138: 22–24.

8. Carosella, E, Gregori, S, Rouas-Freis, N, LeMaoult, J, Menier, C and Favier, B (2011). The role of HLA-G in immunity and hematopoiesis. Cell Mol Life Sci 68: 353–368.

9. Fainardi, E, Castellazzi, M, Stignani, M, Morandi, F, Sana, G, Gonzalez, R et al. (2011). Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci 68: 433–451.

10. Nasef, A, Mattheiu, N, Chapel, A, Frick, J, Francois, S, Mazurier, C et al. (2007). Immunomodulatory effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84: 231–237.

11. Deschaseaux, F, Delgado, D, Pistoia, V, Giuliani, M, Morandi, F and Durrbach, A (2011). HLA-G in organ transplantation: towards clinical applications. Cell Mol Life Sci 68: 397–404.

12. Chiusolo, P, Bellesi, S, Piccirillo, N, Giammarco, S, Marietti, S, De Ritis, D et al. (2012). The role of HLA-G: 14-bp polymorphism in allo-HSCT after short-term course MTX for GVHD prophylaxis. Bone Marrow Transplant 47: 120–124.

13. Naji, A, Rouas-Freis, N, Durrbach, A, Carosella, ED, Sensébé, L and Deschaseaux, F (2013). Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy. Stem Cells 31: 2296–2303.

14. Spaggiari, GM, Capobianco, A, Becchetti, S, Mingari, MC and Moretta, L (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107: 1484–1490.

15. Crop, MI, Korevaar, SS, de Kuiper, R, Uzerman, JN, van Besouw, NM, Baan, CC et al. (2011). Human mesenchymal stem cells are susceptible to lysis by CD8(+T) cells and NK cells. Cell Transplant 20: 1547–1559.

16. Soland, MA, Bego, MG, Colletti, E, Porada, CD, Zanjani, ED, St-Jeor, S et al. (2010). Modulation of human mesenchymal stem cell immunogenicity through forced expression of human cytomegalovirus us proteins. PLoS One 5: e36136.

17. Ankrum, JA, Ong, JF and Karp JM (2014). Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol.

18. Kay, MA, Glorioso JC and Naldini L (2001). Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7: 33–40.

19. Ginn, SL, Alexander, I, Edelstein, ML, Abdi, MR and Wixon J (2013). Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 15: 65–77.

20. Patel, SA, Meyer, J, Greco, SJ, Corcoran, KE, Bryan, M and Rameshwar, P (2010). Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 184: 5885–5894.

21. Barber, DF and Long, EO (2003). Coexpression of CD58 or CD48 with intercellular adhesion molecule 1 on target cells enhances adhesion of resting NK cells. J Immunol 170: 354–361.

22. Ong, J, Derfoul, A, Olsen, D, Hall, DJ et al. (2014). Optimization of high-efficiency transfection of adult human mesenchymal stem cells in vitro. Mol Biotechnol 50: 9–20.

23. Aluigi, M, Fogli, M, Curti, A, Isidori, A, Gruppioni, E, Chiodoni, C et al. (2006). Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng 12: 877–889.

24. Aluigi, M, Fogli, M, Curti, A, Isidori, A, Gruppioni, E, Chiodoni, C et al. (2006). Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells 24: 454–461.

25. Haleem-Smith, H, Derfoul, A, Okafor, C, Tuli, B, Olsen, D, Hall, DJ et al. (2005). Optimization of high-efficiency transfection of adult human mesenchymal stem cells in vitro. Mol Biotechnol 30: 110–128.

26. Haleem-Smith, H, Derfoul, A, Okafor, C, Tuli, B, Olsen, D, Hall, DJ et al. (2005). Optimization of high-efficiency transfection of adult human mesenchymal stem cells in vitro. Mol Biotechnol 30: 9–20.

27. Mauritius, R, De Semis, D, Emamekhoo, H, Bedayat, B, Abdolmohammadi, A, Parisi, H et al. (2010). Comparative transfection of DNA into primary and transformed mammalian cells from different lineages. BMC Biotechnol 10: 9.
30. Kay, MA, He, CY and Chen, ZY (2010). A robust system for production of minicircle DNA vectors. Nat Biotechnol 28: 1287–1289.
31. Gill, DR, Pringle, IA and Hyde, SC (2009). Progress and prospects: the design and production of plasmid vectors. Gene Ther 16: 165–171.
32. Mairhofer, J and Grabherr, R (2008). Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA. Mol Biotechnol 39: 97–104.
33. Walker, WE, Booth, CJ and Goldstein, DR (2010). TLR9 and IFN-γ cooperate to induce a systemic inflammatory response in mice injected with liposome-DNA. Mol Ther 18: 775–784.
34. Madeira, C, Ribeiro, SC, Pinheiro, IS, Martins, SA, Andrade, PZ, da Silva, CL et al. (2011). Gene delivery to human bone marrow mesenchymal stem cells by microinjection. J Biotechnol 151: 130–136.
35. Hwa Cho, H, Bae, YC and Jung, JS (2006). Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 24: 2744–2752.
36. Liotta, F, Angeli, R, Cosmi, L, Filli, L, Manuelli, C, Frosali, F et al. (2008). Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26: 279–289.
37. Delarosa, O, Dalemans, W and Lombardo, E (2012). Toll-like receptors as modulators of mesenchymal stem cells. Front Immunol 3: 182.
38. Raiscevic, G, Rouas, R, Najar, M, Stordeur, P, Boufker, H, Bron, D et al. (2010). Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum Immunol 71: 235–244.
39. Romieu-Mourez, R, François, M, Boivin, MN, Bouchentouf, M, Spaner, DE and Galipeau, J (2009). Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 182: 7963–7973.
40. Giuliani, M, Bennaceur-Griscelli, A, Nanbakhsh, A, Ouahiri, N, Chouaib, S, Azzarone, B et al. (2014). TLR ligands stimulation protects MSC from NK killing. Stem Cells 32: 290–300.
41. Waterman, RS, Tomchuck, SL, Henkle, SL and Betancourt, AM (2010). A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 5: e10088.
42. Nurminiemini, S, Kuvaja, P, Lehtonen, S, Turanieniemi, S, Alahuhta, J, Mattila, RK et al. (2010). Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13. Exp Cell Res 316: 2676–2682.
43. Wang, X, Moghimi, B, Zolotukhin, I, Morel, LM, Cao, O and Herzog, RW (2014). Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells. Mol Ther 22: 1139–1150.
44. Chamberlain, J, Yamagami, T, Colletti, E, Theise, ND, Desai, J, Frias, A et al. (2007). Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. Hepatology 46: 1935–1945.
45. Gong, JH, Maki, G and Klingemann, HG (1994). Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652–658.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/